Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
link
Tags
fda
archive
medical
biotech
boston blog main
boston top stories
clinical trials
europe blog main
europe top stories
life sciences
national blog main
national top stories
abbvie
alkermes
allergan
arena pharmaceuticals
boulder/denver blog main
boulder/denver top stories
buprenorphine
cancer
cardiovascular disease
cariprazine
colorectal cancer
detroit blog main
detroit top stories
eisai
eli lilly
europe
felipe jain
health
indiana blog main
indiana top stories
jess fiedorowicz
jessica jeffrey
karim calis
lorcaserin
lumateperone
lung cancer
m health fairview
marc goodman
What
drug
11
×
weight
11
×
loss
wegovy
cnet
diabetes
fda
know
new
ozempic
called
medication
medicine
obese
study
appetite
drugs
help
here's
market
medications
mice
obesity
published
push
started
treatment
turned
used
administration
adults
agency
alcoholism
alkermes
antipsychotic
approved
approves
banned
believe
benefits
Language
unset
Current search:
weight
×
drug
×
@cnet.com
1 year ago
Ozempic, Wegovy Make for Flashy New Weight-Loss Drugs. Here's What to Know - CNET
@cnet.com
1 year ago
Ozempic, Wegovy and the Evolving Weight-Loss Drug Market - CNET
@cnet.com
1 year ago
Here's What to Know About Ozempic and Wegovy - CNET
@cnet.com
1 year ago
What to Know About Ozempic, Wegovy and the Weight-Loss Drug Debate - CNET
@bgr.com
1 year ago
Scientists demonstrate the effectiveness of this migraine drug for weight loss
@slashgear.com
2 years ago
FDA warns supplement sold on eBay contains banned weight loss drug
@slashgear.com
2 years ago
FDA approves powerful appetite suppressant for obese adults
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@slashgear.com
3 years ago
Alcoholism drug linked to ‘dramatic’ weight loss in obesity study
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@WIRED
8 years ago
The black box warning along with institutional skittishness related to weight-loss medication means Novo Nordisk wants to push extra hard to get doctors ...